

Oncology Clinic Appointment Report

Patient Information

Name: John Doe
DOB: January 15, 1970
Email: john.doe@example.com
Allergies: None
Medical Record Number: 123456

Appointment Details

Date: May 19, 2024
Time: 10:00 AM
Doctor: Dr. Jane Smith, MD

Chief Complaint

Patient presents for a follow-up appointment regarding ongoing treatment for non-small cell lung cancer (NSCLC).

History of Present Illness

John Doe is a 54-year-old male with a diagnosis of Stage IIIA non-small cell lung cancer, initially diagnosed in February 2023. The patient has undergone 6 cycles of cisplatin and pemetrexed chemotherapy, with concurrent radiation therapy completed in October 2023. The patient reports persistent fatigue and mild shortness of breath but denies any new or worsening symptoms.

Past Medical History

- Hypertension
- Type 2 Diabetes Mellitus
- Hyperlipidemia

Medications

- Cisplatin:** 75 mg/m² IV every 3 weeks
- Pemetrexed:** 500 mg/m² IV every 3 weeks
- Metformin:** 500 mg PO BID
- Lisinopril:** 20 mg PO QD
- Atorvastatin:** 40 mg PO QD

Review of Systems

- Constitutional:** Fatigue, weight stable
- Respiratory:** Mild shortness of breath, no cough or hemoptysis
- Cardiovascular:** No chest pain or palpitations

- **Gastrointestinal:** No nausea, vomiting, or diarrhea
- **Neurological:** No headaches, dizziness, or focal deficits

Physical Examination

- **General:** Alert, oriented, no acute distress
- **Vital Signs:** BP 130/85, HR 78, RR 18, Temp 98.6°F, SpO2 96% on room air
- **HEENT:** Normocephalic, atraumatic, no lymphadenopathy
- **Chest/Lungs:** Clear to auscultation bilaterally, no wheezes or crackles
- **Cardiovascular:** Regular rate and rhythm, no murmurs or gallops
- **Abdomen:** Soft, non-tender, no hepatosplenomegaly
- **Extremities:** No edema, pulses intact
- **Neurological:** Intact cranial nerves, no focal deficits

Assessment

- **Non-small cell lung cancer (NSCLC), Stage IIIA, stable post-chemoradiation**
- **Hypertension, controlled**
- **Type 2 Diabetes Mellitus, controlled**
- **Hyperlipidemia, controlled**

Plan

1. Continue current chemotherapy regimen of cisplatin and pemetrexed.
2. Schedule PET-CT scan in 4 weeks to assess response to treatment.
3. Monitor blood glucose levels; adjust Metformin dosage as needed.
4. Follow-up appointment in 6 weeks to review scan results and assess overall health.
5. Encourage patient to maintain a healthy diet and exercise routine to manage fatigue and overall well-being.

Patient Education

Discussed potential side effects of ongoing chemotherapy, including nausea, fatigue, and risk of infection. Emphasized the importance of hydration and adherence to medication regimen. Provided resources for support groups and nutritional counseling.

Signed:

Dr. Jane Smith, MD

Oncologist, Vita Clinic

jane.smith@vitaclinic.com